Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 13/20 | 0.41 |
| ▸ | ACACA | Q13085 | 10/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17453589 | 1.00 | SPR (0.42) | SPRACACBACACAPBKCKS1B | |
| SCHEMBL30642247 | 0.88 | BTK (0.42) | CKS1BSKP1SKP2ADORA2A | |
| SCHEMBL30642239 | 0.86 | SPR (0.40) | SPRACACBACACAPBKCKS1B | |
| SCHEMBL17453585 | 0.86 | SPR (0.40) | SPRACACBACACAPBKCKS1B | |
| SCHEMBL15656647 | 0.85 | IRAK4 (0.38) | ADORA2A | |
| SCHEMBL15656648 | 0.85 | IRAK4 (0.38) | ADORA2A | |
| SCHEMBL15655413 | 0.80 | ALDH1A1 (0.47) | ADORA2A | |
| SCHEMBL17440271 | 0.79 | IRAK4 (0.39) | — | |
| SCHEMBL17440273 | 0.79 | IRAK4 (0.39) | — | |
| SCHEMBL15656707 | 0.79 | IRAK4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | SPR 2038/4885ACACB 3152/4885ACACA 3104/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | SPR 2038/4885ACACB 3152/4885ACACA 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.